Dual therapy for third-line helicobacter pylori eradication and urea Breath test prediction

Toshihiro Nishizawa, Hidekazu Suzuki, Takama Maekawa, Naohiko Harada, Tatsuya Toyokawa, Toshio Kuwai, Masanori Ohara, Takahiro Suzuki, Masahiro Kawanishi, Kenji Noguchi, Toshiyuki Yoshio, Shinji Katsushima, Hideo Tsuruta, Eiji Masuda, Munehiro Tanaka, Shunsuke Katayama, Norio Kawamura, Yuko Nishizawa, Toshifumi Hibi, Masahiko Takahashi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We evaluated the efficacy and tolerability of a dual therapy with rabeprazole and amoxicillin (AMX) as an empiric third-line rescue therapy. In patients with failure of first-line treatment with a proton pump inhibitor (PPI)-AMX-clarithromycin regimen and second-line treatment with the PPI-AMX-metronidazole regimen, a third-line eradication regimen with rabeprazole (10 mg q.i.d.) and AMX (500 mg q.i.d.) was prescribed for 2 wk. Eradication was confirmed by the results of the 13C-urea breath test (UBT) at 12 wk after the therapy. A total of 46 patients were included; however, two were lost to follow-up. The eradication rates as determined by per-protocol and intention-to-treat analyses were 65.9% and 63.0%,respectively. The pretreatment UBT results in the subjects showing eradication failure; those patients showing successful eradication comprised 32.9 ± 28.8 permil and 14.8 ± 12.8 permil, respectively. The pretreatment UBT results in the subjects with eradication failure were significantly higher than those in the patients with successful eradication (P= 0.019). A low pretreatment UBT result (≤ 28.5 permil) predicted the success of the eradication therapy with a positive predictive value of 81.3% and a sensitivity of 89.7%. Adverse effects were reported in 18.2% of the patients, mainly diarrhea and stomatitis. Dual therapy with rabeprazole and AMX appears to serve as a potential empirical third-line strategy for patients with low values on pretreatment UBT.

Original languageEnglish
Pages (from-to)2735-2738
Number of pages4
JournalWorld Journal of Gastroenterology
Volume18
Issue number21
DOIs
Publication statusPublished - 2012 Jun

Fingerprint

Breath Tests
Helicobacter pylori
Urea
Amoxicillin
Rabeprazole
Proton Pump Inhibitors
Therapeutics
Stomatitis
Intention to Treat Analysis
Clarithromycin
Lost to Follow-Up
Metronidazole
Diarrhea

Keywords

  • Amoxicillin
  • Dual therapy
  • Eradication
  • Helicobacter pylori
  • Urea breath test

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Nishizawa, T., Suzuki, H., Maekawa, T., Harada, N., Toyokawa, T., Kuwai, T., ... Takahashi, M. (2012). Dual therapy for third-line helicobacter pylori eradication and urea Breath test prediction. World Journal of Gastroenterology, 18(21), 2735-2738. https://doi.org/10.3748/wjg.v18.i21.2735

Dual therapy for third-line helicobacter pylori eradication and urea Breath test prediction. / Nishizawa, Toshihiro; Suzuki, Hidekazu; Maekawa, Takama; Harada, Naohiko; Toyokawa, Tatsuya; Kuwai, Toshio; Ohara, Masanori; Suzuki, Takahiro; Kawanishi, Masahiro; Noguchi, Kenji; Yoshio, Toshiyuki; Katsushima, Shinji; Tsuruta, Hideo; Masuda, Eiji; Tanaka, Munehiro; Katayama, Shunsuke; Kawamura, Norio; Nishizawa, Yuko; Hibi, Toshifumi; Takahashi, Masahiko.

In: World Journal of Gastroenterology, Vol. 18, No. 21, 06.2012, p. 2735-2738.

Research output: Contribution to journalArticle

Nishizawa, T, Suzuki, H, Maekawa, T, Harada, N, Toyokawa, T, Kuwai, T, Ohara, M, Suzuki, T, Kawanishi, M, Noguchi, K, Yoshio, T, Katsushima, S, Tsuruta, H, Masuda, E, Tanaka, M, Katayama, S, Kawamura, N, Nishizawa, Y, Hibi, T & Takahashi, M 2012, 'Dual therapy for third-line helicobacter pylori eradication and urea Breath test prediction', World Journal of Gastroenterology, vol. 18, no. 21, pp. 2735-2738. https://doi.org/10.3748/wjg.v18.i21.2735
Nishizawa, Toshihiro ; Suzuki, Hidekazu ; Maekawa, Takama ; Harada, Naohiko ; Toyokawa, Tatsuya ; Kuwai, Toshio ; Ohara, Masanori ; Suzuki, Takahiro ; Kawanishi, Masahiro ; Noguchi, Kenji ; Yoshio, Toshiyuki ; Katsushima, Shinji ; Tsuruta, Hideo ; Masuda, Eiji ; Tanaka, Munehiro ; Katayama, Shunsuke ; Kawamura, Norio ; Nishizawa, Yuko ; Hibi, Toshifumi ; Takahashi, Masahiko. / Dual therapy for third-line helicobacter pylori eradication and urea Breath test prediction. In: World Journal of Gastroenterology. 2012 ; Vol. 18, No. 21. pp. 2735-2738.
@article{f34bde05d0a34ce2948a6e4d1dbf0271,
title = "Dual therapy for third-line helicobacter pylori eradication and urea Breath test prediction",
abstract = "We evaluated the efficacy and tolerability of a dual therapy with rabeprazole and amoxicillin (AMX) as an empiric third-line rescue therapy. In patients with failure of first-line treatment with a proton pump inhibitor (PPI)-AMX-clarithromycin regimen and second-line treatment with the PPI-AMX-metronidazole regimen, a third-line eradication regimen with rabeprazole (10 mg q.i.d.) and AMX (500 mg q.i.d.) was prescribed for 2 wk. Eradication was confirmed by the results of the 13C-urea breath test (UBT) at 12 wk after the therapy. A total of 46 patients were included; however, two were lost to follow-up. The eradication rates as determined by per-protocol and intention-to-treat analyses were 65.9{\%} and 63.0{\%},respectively. The pretreatment UBT results in the subjects showing eradication failure; those patients showing successful eradication comprised 32.9 ± 28.8 permil and 14.8 ± 12.8 permil, respectively. The pretreatment UBT results in the subjects with eradication failure were significantly higher than those in the patients with successful eradication (P= 0.019). A low pretreatment UBT result (≤ 28.5 permil) predicted the success of the eradication therapy with a positive predictive value of 81.3{\%} and a sensitivity of 89.7{\%}. Adverse effects were reported in 18.2{\%} of the patients, mainly diarrhea and stomatitis. Dual therapy with rabeprazole and AMX appears to serve as a potential empirical third-line strategy for patients with low values on pretreatment UBT.",
keywords = "Amoxicillin, Dual therapy, Eradication, Helicobacter pylori, Urea breath test",
author = "Toshihiro Nishizawa and Hidekazu Suzuki and Takama Maekawa and Naohiko Harada and Tatsuya Toyokawa and Toshio Kuwai and Masanori Ohara and Takahiro Suzuki and Masahiro Kawanishi and Kenji Noguchi and Toshiyuki Yoshio and Shinji Katsushima and Hideo Tsuruta and Eiji Masuda and Munehiro Tanaka and Shunsuke Katayama and Norio Kawamura and Yuko Nishizawa and Toshifumi Hibi and Masahiko Takahashi",
year = "2012",
month = "6",
doi = "10.3748/wjg.v18.i21.2735",
language = "English",
volume = "18",
pages = "2735--2738",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "21",

}

TY - JOUR

T1 - Dual therapy for third-line helicobacter pylori eradication and urea Breath test prediction

AU - Nishizawa, Toshihiro

AU - Suzuki, Hidekazu

AU - Maekawa, Takama

AU - Harada, Naohiko

AU - Toyokawa, Tatsuya

AU - Kuwai, Toshio

AU - Ohara, Masanori

AU - Suzuki, Takahiro

AU - Kawanishi, Masahiro

AU - Noguchi, Kenji

AU - Yoshio, Toshiyuki

AU - Katsushima, Shinji

AU - Tsuruta, Hideo

AU - Masuda, Eiji

AU - Tanaka, Munehiro

AU - Katayama, Shunsuke

AU - Kawamura, Norio

AU - Nishizawa, Yuko

AU - Hibi, Toshifumi

AU - Takahashi, Masahiko

PY - 2012/6

Y1 - 2012/6

N2 - We evaluated the efficacy and tolerability of a dual therapy with rabeprazole and amoxicillin (AMX) as an empiric third-line rescue therapy. In patients with failure of first-line treatment with a proton pump inhibitor (PPI)-AMX-clarithromycin regimen and second-line treatment with the PPI-AMX-metronidazole regimen, a third-line eradication regimen with rabeprazole (10 mg q.i.d.) and AMX (500 mg q.i.d.) was prescribed for 2 wk. Eradication was confirmed by the results of the 13C-urea breath test (UBT) at 12 wk after the therapy. A total of 46 patients were included; however, two were lost to follow-up. The eradication rates as determined by per-protocol and intention-to-treat analyses were 65.9% and 63.0%,respectively. The pretreatment UBT results in the subjects showing eradication failure; those patients showing successful eradication comprised 32.9 ± 28.8 permil and 14.8 ± 12.8 permil, respectively. The pretreatment UBT results in the subjects with eradication failure were significantly higher than those in the patients with successful eradication (P= 0.019). A low pretreatment UBT result (≤ 28.5 permil) predicted the success of the eradication therapy with a positive predictive value of 81.3% and a sensitivity of 89.7%. Adverse effects were reported in 18.2% of the patients, mainly diarrhea and stomatitis. Dual therapy with rabeprazole and AMX appears to serve as a potential empirical third-line strategy for patients with low values on pretreatment UBT.

AB - We evaluated the efficacy and tolerability of a dual therapy with rabeprazole and amoxicillin (AMX) as an empiric third-line rescue therapy. In patients with failure of first-line treatment with a proton pump inhibitor (PPI)-AMX-clarithromycin regimen and second-line treatment with the PPI-AMX-metronidazole regimen, a third-line eradication regimen with rabeprazole (10 mg q.i.d.) and AMX (500 mg q.i.d.) was prescribed for 2 wk. Eradication was confirmed by the results of the 13C-urea breath test (UBT) at 12 wk after the therapy. A total of 46 patients were included; however, two were lost to follow-up. The eradication rates as determined by per-protocol and intention-to-treat analyses were 65.9% and 63.0%,respectively. The pretreatment UBT results in the subjects showing eradication failure; those patients showing successful eradication comprised 32.9 ± 28.8 permil and 14.8 ± 12.8 permil, respectively. The pretreatment UBT results in the subjects with eradication failure were significantly higher than those in the patients with successful eradication (P= 0.019). A low pretreatment UBT result (≤ 28.5 permil) predicted the success of the eradication therapy with a positive predictive value of 81.3% and a sensitivity of 89.7%. Adverse effects were reported in 18.2% of the patients, mainly diarrhea and stomatitis. Dual therapy with rabeprazole and AMX appears to serve as a potential empirical third-line strategy for patients with low values on pretreatment UBT.

KW - Amoxicillin

KW - Dual therapy

KW - Eradication

KW - Helicobacter pylori

KW - Urea breath test

UR - http://www.scopus.com/inward/record.url?scp=84863093027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863093027&partnerID=8YFLogxK

U2 - 10.3748/wjg.v18.i21.2735

DO - 10.3748/wjg.v18.i21.2735

M3 - Article

C2 - 22690086

AN - SCOPUS:84863093027

VL - 18

SP - 2735

EP - 2738

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 21

ER -